What does CUSIP 92686J106 represent in this 13F holders report?

CUSIP 92686J106 is the security identifier for VKTX - Viking Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held VKTX - Viking Therapeutics, Inc. - Common Stock in Q1 2016?

6 institutional investors reported VKTX - Viking Therapeutics, Inc. - Common Stock for Q1 2016. Use the holders table for investor-level position and value details.

Viking Therapeutics, Inc. - Common Stock (VKTX)

CUSIP: 92686J106

Q1 2016 13F Holders as of 31 Mar 2016

Type / Class: Equity / Common Stock
Shares outstanding: 115,694,154
Total 13F shares: 44,443
Share change: +3,165
Total reported value: $65,000
Price per share: $1.53
Number of holders: 6
Value change: -$25,998
Number of buys: 5
Number of sells: 3

Quarterly Holders Quick Answers

What is CUSIP 92686J106?
CUSIP 92686J106 identifies VKTX - Viking Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2016
Previous quarter: Q4 2015

Recent filing periods for CUSIP 92686J106:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of VKTX - Viking Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
VANGUARD GROUP INC	13F	Company	0.02%	18,875	$64,000	—	31 Dec 2015	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.01%	12,826	$44,000	—	31 Dec 2015	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.01%	6,250	$21,000	—	31 Dec 2015	13F
ROYAL BANK OF CANADA	13F	Company	0%	3,125	$18,000	—	31 Dec 2015	13F
Creative Planning	13F	Company	0%	3,000	$10,000	—	31 Dec 2015	13F
BlackRock Investment Management, LLC	13F	Company	0%	327	$1,000	—	31 Dec 2015	13F

Institutional Holders of Viking Therapeutics, Inc. - Common Stock (VKTX) as of Q1 2016

As of 31 Mar 2016, Viking Therapeutics, Inc. - Common Stock (VKTX) was held by 6 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 44,443 shares. The largest 6 holders included VANGUARD GROUP INC, CITADEL ADVISORS LLC, WELLS FARGO & COMPANY/MN, UBS Group AG, MANUFACTURERS LIFE INSURANCE COMPANY, THE, and BlackRock Fund Advisors. This page lists 6 institutional shareholders reporting positions in this security for the Q1 2016 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2016 vs Q4 2015 Across Filers

Q4 2015 holders

Q1 2016 holders

Holder diff

Investor	Q4 2015 Shares	Q1 2016 Shares	Share Diff	Share Chg %	Q4 2015 Value $	Q1 2016 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.